secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2024-03-14T23:59:59+00:00
Accession:  0001193125-24-067471
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Amylyx appoints Dr. Bernhardt Zeiher to board, fills Class I director vacancy
-----------------------------------------------------------------------------

- Appointed March 14, 2024 as Class I director; term expires at 2025 annual meeting.
- Also named to Nominating and Corporate Governance Committee, replacing Paul Fonteyne.
- Zeiher was Chief Medical Officer at Astellas Pharma from 2018-2022; joined Entrada Therapeutics board in 2023.
- Receives initial option grant (lesser of $570K value or 50K shares); 1/3 vests at one year, remainder over two years.
- Annual retainer of $45,000 plus $5,000 for Nominating Committee service; eligible for annual option grants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000119312524067471/0001193125-24-067471-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000119312524067471/d789002d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-067471

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer